Global Digital Pathology Market, by Offering (Scanner (Bright Field Scanner, Fluorescence Scanner), Software (Image Analysis Platform(On-Premises Delivery, Cloud Based Delivery), DPIS(On-Premises Delivery, Cloud Based Delivery), Services(Installation and Integration, Maintenance Services, Consulting Services)), by Application (Hematology, Chemical Pathology, Histopathology, Medical Microbiology), by End User (Hospitals, Laboratories (Private Laboratories, Public Laboratories, Research center ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 666.0 Million in 2022 and is expected to exhibit a CAGR of 7.7% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key players in the market are focused on launching new products in the market which is expected to drive the market over the forecast period. For instance, in October 2021, Koninklijke Philips N.V., medical device company, introduced its new enterprise-wide digital pathology platform called IntelliSite. The product features a suite of scalable software tools designed to streamline workflows, enhance diagnostic confidence, facilitate collaboration, integrate artificial intelligence (AI) and increase the efficiency of pathology labs, Philips said in its announcement. IntelliSite can be deployed in labs both small and large with its ability to conduct multi-layer slide scanning. It can also optimize pathology workflows by integrating into laboratory information systems and with its image management system that allows for multidisciplinary case reviews.
Global Digital Pathology Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global digital pathology market, owing to increase in technology advances and increase in demand for diagnosis of COVID-19 infection. For instance, in May 2021, according to the data published by the National Center for Biotechnology Information, during the pandemic, the widespread use of digital tools in institution allowed a smooth transition of most clinical and academic activities into remote with no major disruptions. The number of pathologists using whole slide imaging (WSI) for primary diagnosis increased from 20 (62.5%) to 29 (90.6%) of a total of 32 pathologists, excluding renal pathology and hematopathology, during the pandemic.
Moreover, in November 2020, Koninklijke Philips N.V., a health technology, announced leading pathology laboratories across North America, Europe, and Asia have implemented full digitization for their histology samples based on the Philips Digital Pathology scanner and imaging-informatics solutions. Digital images are required to unlock the potential of digital pathology. Remote reviewing of pathological cases is essential to prevent delay in critical patient diagnosis and care, particularly during COVID-19. During the pandemic, many pathologists, oncologists, and radiologists continued their work from home. This created an unprecedented need for home workstations and secure clinical informatics solutions allowing clinicians to read images remotely and enabling real-time virtual collaboration between their multi-disciplinary care teams.
Global Digital Pathology Market: Key Developments
In April 2022, GlaxoSmithKline Pharmaceuticals Ltd, pharmaceutical company recruits PathAI, Inc., pathology lab using machine learning to bring digital pathology AI to cancer for Non-alcoholic Steatohepatitis (NASH) drug development. GSK’s computational pathology algorithms on PathAI’s platform to support clinical trials and use PathAI’s own algorithms to advance the Big Pharma’s clinical development targeting NASH, PathAI CEO Andy Beck, M.D., Ph.D., told Fierce Medtech. PathAI’s digital tools use AI and deep learning technology to analyze tissue samples, looking for condition-specific biomarkers that can predict how a disease will progress and how an individual patient might react to various treatments.
Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Digital Pathology Market”- Forecast to 2030, Global Digital Pathology Market, by Offering (Scanner (Bright Field Scanner, Fluorescence Scanner), Software (Image Analysis Platform(On-Premises Delivery, Cloud Based Delivery), DPIS(On-Premises Delivery, Cloud Based Delivery), Services(Installation and Integration, Maintenance Services, Consulting Services)), by Application (Hematology, Chemical Pathology, Histopathology, Medical Microbiology), End User (Hospitals, Laboratories (Private Laboratories, Public Laboratories, Research Centers ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Moreover, increasing clinical and preclinical trials are expected to boost growth of the global digital pathology market. For instance, in March 2019, ClinicalTrials.gov, official site for checking pipeline drugs listed 298,856 registered studies under clinical trials.
Key Takeaways of the Global Digital Pathology Market: